Your browser doesn't support javascript.
loading
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
Moore, Andrew S; Faisal, Amir; Mak, Grace W Y; Miraki-Moud, Farideh; Bavetsias, Vassilios; Valenti, Melanie; Box, Gary; Hallsworth, Albert; de Haven Brandon, Alexis; Xavier, Cristina P R; Stronge, Randal; Pearson, Andrew D J; Blagg, Julian; Raynaud, Florence I; Chopra, Rajesh; Eccles, Suzanne A; Taussig, David C; Linardopoulos, Spiros.
Afiliación
  • Moore AS; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Faisal A; Paediatric Oncology, Royal Marsden Hospital, Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom.
  • Mak GWY; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Miraki-Moud F; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Bavetsias V; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Valenti M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Hallsworth A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • de Haven Brandon A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Xavier CPR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Stronge R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Pearson ADJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Blagg J; Haemato-Oncology Section, Royal Marsden Hospital, Sutton, United Kingdom; and.
  • Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Chopra R; Paediatric Oncology, Royal Marsden Hospital, Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom.
  • Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Taussig DC; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
  • Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.
Blood Adv ; 4(7): 1478-1491, 2020 04 14.
Article en En | MEDLINE | ID: mdl-32282883
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Leucemia Mieloide Aguda Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Leucemia Mieloide Aguda Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido